EA201690861A1 - NUCLEIN-ACID MODULATORS OF PROTEIN ALPHA2BETA1 - Google Patents

NUCLEIN-ACID MODULATORS OF PROTEIN ALPHA2BETA1

Info

Publication number
EA201690861A1
EA201690861A1 EA201690861A EA201690861A EA201690861A1 EA 201690861 A1 EA201690861 A1 EA 201690861A1 EA 201690861 A EA201690861 A EA 201690861A EA 201690861 A EA201690861 A EA 201690861A EA 201690861 A1 EA201690861 A1 EA 201690861A1
Authority
EA
Eurasian Patent Office
Prior art keywords
nucleic acid
protein
nuclein
acid ligand
modulator
Prior art date
Application number
EA201690861A
Other languages
Russian (ru)
Inventor
Кристофер Рускони
Джулиана Лейзер
Original Assignee
ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" filed Critical ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика"
Publication of EA201690861A1 publication Critical patent/EA201690861A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/7055—Integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Предлагаются композиции, включающие нуклеиновокислотый лиганд и/или модулятор, а также способы применения этих агентов и композиций в лечении α2β1-опосредованных заболеваний и нарушений. Также предлагается фармакологическая система, содержащая нуклеиновокислотный лиганд, который связывается с белком интегрином α2β1 и регулирует его активность. Кроме того, эти нуклеиновокислотные лиганды активно обратимы при использовании модулятора, который ингибирует активность нуклеиновокислотного лиганда с нейтрализацией его фармакологического эффекта, тем самым восстанавливает функцию α2β1.Compositions are proposed that include a nucleic acid ligand and / or a modulator, as well as methods for using these agents and compositions in the treatment of α2β1-mediated diseases and disorders. It also proposes a pharmacological system containing a nucleic acid ligand that binds to the α2β1 integrin protein and regulates its activity. In addition, these nucleic acid ligands are actively reversible by using a modulator that inhibits the activity of a nucleic acid ligand with neutralizing its pharmacological effect, thereby restoring the function of α2β1.

EA201690861A 2012-10-24 2013-10-14 NUCLEIN-ACID MODULATORS OF PROTEIN ALPHA2BETA1 EA201690861A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261717944P 2012-10-24 2012-10-24
PCT/US2013/064829 WO2014066084A1 (en) 2012-10-24 2013-10-14 Nucleic acid modulators of alpha2beta1

Publications (1)

Publication Number Publication Date
EA201690861A1 true EA201690861A1 (en) 2016-08-31

Family

ID=50545113

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690861A EA201690861A1 (en) 2012-10-24 2013-10-14 NUCLEIN-ACID MODULATORS OF PROTEIN ALPHA2BETA1

Country Status (2)

Country Link
EA (1) EA201690861A1 (en)
WO (1) WO2014066084A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ521437A (en) * 2000-02-25 2004-04-30 Immunex Corp Integrin antagonists suitable as inhibitors of angiogenesis
AU2775402A (en) * 2001-06-29 2003-01-02 Medimolecular Pty Ltd Nucleic acid ligands to complex targets
ES2494940T3 (en) * 2004-04-22 2014-09-16 Regado Biosciences, Inc. Enhanced coagulation factor modulators

Also Published As

Publication number Publication date
WO2014066084A1 (en) 2014-05-01

Similar Documents

Publication Publication Date Title
CY1119058T1 (en) IMIDAZOPYRROLIDINONE COMPOUNDS
EA201791093A1 (en) ANTIBODIES TO CD47, METHODS AND USE
EA201391019A1 (en) CONNECTIONS AND METHODS FOR KINAZ MODULATION AND ALSO THE INDICATIONS TO THEIR APPLICATION
EA201400993A1 (en) ANTIBODIES AGAINST THE EPIDERMAL GROWTH FACTOR RECEPTOR, ACTIVE IN CERTAIN CONDITIONS AND METHODS OF THEIR APPLICATION
EA201690567A1 (en) ANTIBODIES AGAINST PD1 AND THEIR APPLICATION AS THERAPEUTIC AND DIAGNOSTIC MEANS
EA201492219A1 (en) CONNECTIONS AND COMPOSITIONS FOR EGFR MODULATION OF ACTIVITY
EA201491811A1 (en) ANTI-LgR5 ANTIBODIES AND IMMUNOCONJUGATES
EA201491541A1 (en) ANTIBODIES AGAINST αvβ6 INTEGRINES AND THEIR APPLICATION FOR THE TREATMENT OF MALIGNANT NOROVES
UY34995A (en) FORMULATIONS OF ANTIBODY AND PROTEIN
EA202090031A3 (en) HUMAN ANTIBODIES AGAINST GFR3 AND METHODS OF THEIR USE
EA201690881A1 (en) COMPOUNDS INHIBITORS AUTOTAXIN
EA201591430A1 (en) COMPOUNDS AND THEIR APPLICATIONS FOR MODULATION OF HEMOGLOBIN
AR090903A1 (en) ANTI-PMEL ANTIBODIES AND IMMUNOCADES17
EA201500314A1 (en) DOSAGE FORMS OF ENZALUTAMIDE
DK2831241T3 (en) ARTIFICIAL NUCLEIC ACID MOLECULES FOR IMPROVED PROTEIN OR PEPTIDE EXPRESSION.
WO2014031646A3 (en) Molecules with antigen binding and polyvalent fc gamma receptor binding activity
EA201591762A1 (en) HUMAN ANTIBODIES TO GREM1
EA201491530A1 (en) MODULATORS OF ESTROGEN RECEPTORS AND THEIR APPLICATION
EA201492040A1 (en) BICYCLICALLY SUBSTITUTED URACILES AND THEIR APPLICATION
EA201300137A1 (en) COMBINED PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES OR CONDITIONS ASSOCIATED WITH NEURODEGENERATIVE DISEASES
EA201591191A1 (en) ANTIBODIES AGAINST NTB-A AND RELATED COMPOSITIONS AND METHODS
EA201491610A1 (en) MODULATORS X LIVER RECEPTORS
EA201591618A1 (en) SUBSTITUTED IMIDAZOPIRIDAZINES
EA201500363A8 (en) HUMAN ANTI-VEGFR-2 / KDR-ANTIBODIES
EA201790773A1 (en) COMPOSITIONS AND METHODS FOR INHIBITING BIOLOGICAL ACTIVITY OF SOLUBLE BIOMOLECULES